论文部分内容阅读
本刊讯对专利药品、独家生产药品,建立公开透明、多方参与的药品价格谈判机制,是深化医药卫生体制改革、推进公立医院药品集中采购、降低广大患者用药负担的重要举措。2016年5月20日,首批国家药品价格谈判结果向社会公布,其中有慢性乙型肝炎一线治疗药物替诺福韦酯,非小细胞肺癌靶向治疗药物埃克替尼和吉非替尼。与之前公立医院的采购价格比较,3种谈判药品价格降幅均在50%以上,与周边
The publication of proprietary drugs, exclusive drug production, the establishment of an open, multi-participatory drug price negotiation mechanism is an important measure to deepen the reform of the medical and health system, to promote centralized procurement of drugs in public hospitals and reduce the burden on the majority of patients medication. May 20, 2016, the first batch of results of the national drug price negotiations announced to the community, including first-line treatment of chronic hepatitis B tenofovir disoproxil, non-small cell lung cancer targeted drugs imatinib and gefitinib . Compared with the previous purchase price of public hospitals, the prices of the three negotiated medicines dropped by more than 50%